Investigating how DHRS9 affects the metabolism of lipid mediators involved in inflammation.
Official title: Role of DHRS9 in oxylipin metabolism
Funded at University of Alabama at Birmingham · NIH-11077282 · Data updated 2026-11-12
This study is looking at how a specific enzyme called DHRS9 affects inflammation in the body, which could help us understand and improve treatments for conditions like acute lung injury.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project start | April 20, 2024 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $621,846 |
| NIH project number | 5R01HL168031-02 |
| Project ID | NIH-11077282 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit would include individuals suffering from acute lung injury or other inflammatory diseases.
✕Less likely to help
Patients with non-inflammatory conditions or those not affected by oxylipin metabolism may not receive any benefit from this research.
What this research studies
This research focuses on understanding the role of DHRS9, an enzyme that influences the metabolism of oxylipins, which are lipid mediators derived from fatty acids. By studying how DHRS9 alters the balance between pro-inflammatory and anti-inflammatory oxylipins, the research aims to uncover mechanisms that could impact conditions like acute lung injury. The approach involves biochemical analyses and animal models to observe the effects of DHRS9 deficiency on inflammation and healing processes. Patients may benefit from insights gained about inflammation regulation and potential new therapeutic targets.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for inflammatory conditions, improving patient outcomes.
How similar studies have gone: Previous research has shown promising results in understanding the role of lipid mediators in inflammation, suggesting that this approach could yield valuable insights.
Where this research is happening
-
University of Alabama at Birmingham
Birmingham, United States Active
Researchers
- Principal investigator: Kedishvili, Natalia Y — University of Alabama at Birmingham
- Study coordinator: Kedishvili, Natalia Y
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.